📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) Tempus AI Par

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) Tempus AI Partners With Angiosarcoma Awareness to Advance Rare Cancer Research

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ 𝐓𝐞𝐦𝐩𝐮𝐬 𝐀𝐈 partnered with 𝐀𝐧𝐠𝐢𝐨𝐬𝐚𝐫𝐜𝐨𝐦𝐚 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 to accelerate rare cancer research.

➤ Collaboration will leverage Tempus' 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫, clinical, and AI analytics capabilities.

➤ Dataset includes approximately 𝟔𝟎𝟎 de-identified angiosarcoma patient records.

➤ Each record contains paired 𝐃𝐍𝐀 and 𝐑𝐍𝐀 sequencing data with clinical information where available.

➤ The dataset represents one of the 𝐥𝐚𝐫𝐠𝐞𝐬𝐭 known molecular resources for angiosarcoma.

➤ Angiosarcoma affects about 𝟏,𝟎𝟎𝟎 people annually in the United States.

➤ Research aims to identify 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐛𝐢𝐨𝐥𝐨𝐠𝐲 and potential therapeutic opportunities.

➤ Collaboration builds on the 𝐀𝐧𝐠𝐢𝐨𝐬𝐚𝐫𝐜𝐨𝐦𝐚 𝐏𝐫𝐨𝐣𝐞𝐜𝐭 launched in 2017.

👉 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:

➤ Larger datasets could improve 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 for rare cancer patients.

➤ Collaboration may accelerate 𝐭𝐚𝐫𝐠𝐞𝐭 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 and future treatment development.

➤ Demonstrates Tempus AI's expanding role in 𝐀𝐈-𝐝𝐫𝐢𝐯𝐞𝐧 oncology research.

👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:

➤ "Angiosarcoma, like many rare cancers, has been understudied because the foundational knowledge needed to develop novel therapy has been limited. Precision medicine should not be limited by the availability of data, especially for patients with uncommon and aggressive cancers. By bringing together Tempus' multimodal molecular and clinical data with collaborative research efforts across the healthcare community, we can fulfill the promise of precision medicine by treating the right patient with the right therapy at the right time." — 𝐄𝐳𝐫𝐚 𝐂𝐨𝐡𝐞𝐧, MD, Chief Medical Officer of Oncology at Tempus.

➤ "Rare cancer research has long been constrained by scale. Patients are geographically dispersed, data is fragmented across institutions and no single organization sees enough cases to answer many of the most important biological and clinical questions. Tempus has assembled an extraordinary molecular and clinical oncology dataset, and the Angiosarcoma Project at the Broad Institute of MIT and Harvard has built one of the largest patient-partnered rare cancer resources in the world. Together, we have an opportunity to create an unprecedented view of angiosarcoma that could reveal new disease biology, identify therapeutic opportunities and establish a model for how collaborative data sharing can accelerate discovery across rare cancers." — 𝐂𝐨𝐫𝐫𝐢𝐞 𝐏𝐚𝐢𝐧𝐭𝐞𝐫, CEO of Angiosarcoma Awareness, Inc